Chardan lowered the firm’s price target on Immuneering to $12 from $16 and keeps a Buy rating on the shares following the Q2 report. The company highlighted upcoming milestones across its pipeline, including initial phase IIa data for IMM-1-104 and initial phase I data for IMM-6-415 in the second half of 2024, the analyst tells investors in a research note.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IMRX:
Questions or Comments about the article? Write to editor@tipranks.com